1438391-30-0
基本信息
化合物CC-401 HYDROCHLORIDE
JNK抑制劑(CC-401 HYDROCHLORIDE)
3-[3-[2-(1-哌啶基)乙氧基]苯基]-5-(1H-1,2,4-三唑-5-基)-1H-吲唑鹽酸鹽
CC-401 dihydrochloride >=95% (HPLC)
CC 401 HYDROCHLORIDE
CC401 HYDROCHLORIDE
CC401 HCL
3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole hydrochloride (1:1)
物理化學(xué)性質(zhì)
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
2024/11/08 | HY-13022 | 3-[3-[2-(1-哌啶基)乙氧基]苯基]-5-(1H-1,2,4-三唑-5-基)-1H-吲唑鹽酸鹽 CC-401 hydrochloride | 1438391-30-0 | 5mg | 900元 |
2024/11/08 | HY-13022 | 3-[3-[2-(1-哌啶基)乙氧基]苯基]-5-(1H-1,2,4-三唑-5-基)-1H-吲唑鹽酸鹽 CC-401 hydrochloride | 1438391-30-0 | 10mM * 1mLin DMSO | 990元 |
2024/11/08 | HY-13022 | 3-[3-[2-(1-哌啶基)乙氧基]苯基]-5-(1H-1,2,4-三唑-5-基)-1H-吲唑鹽酸鹽 CC-401 hydrochloride | 1438391-30-0 | 10mg | 1400元 |
常見問題列表
JNK 25-50 nM (Ki) |
CC-401 has at least 40-fold selectivity for JNK compared with other related kinases, including p38, extracellular signal-regulated kinase (ERK), inhibitor of κB kinase (IKK2), protein kinase C, Lck, zeta-associated protein of 70 kDa (ZAP70). In cell-based assays, 1 to 5 μM CC-401 provides specific JNK inhibition. CC-401, a small molecule that is a specific inhibitor of all three JNK isoforms. CC-401 competitively binds the ATP binding site in JNK, resulting in inhibition of the phosphorylation of the N-terminal activation domain of the transcription factor c-Jun. The specificity of this inhibitor is tested in vitro using osmotic stress of the HK-2 human tubular epithelial cell line. CC-401 inhibits sorbitol-induced phosphorylation of c-Jun in a dosage-dependent manner. However, CC-401 does not prevent sorbitol-induced phosphorylation of JNK, p38, or ERK.
The staining of p-JNK is moderately induced in bevazicumab and Oxaliplatin treatments as compared to control, and in the CC-401-treated samples p-cJun content is significantly lower, consistent with effective JNK inhibition. DNA damage is modestly elevated in combined treatments with CC-401. CC-401 treatment from days 7 to 24 slows the progression of proteinuria, which is significantly reduced compared to the no-treatment and vehicle groups at days 14 and 21. However, there is still an increase in the degree of proteinuria at day 21 in CC-401-treated rats compared to proteinuria at day 5. The vehicle and no-treatment groups developed renal impairment at day 24 as shown by an increase in serum creatinine. This is prevented by CC-401 treatment.